Merck Serono Announces Top-Line Results Of Long-Term Study Of Safinamide As Add-on Treatment To Levodopa In Advanced Parkinson's Disease
GENEVA, Switzerland, November 4, 2010 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, and its partner Newron Pharmaceuticals S.p.A. announced today the top-line results of…